Siravatinib/Tislelizumab Signals Efficacy in Patients With Platinum-Resistant Ovarian Cancer
December 19, 2019 6:00 pmBy Nichole Tucker
Preliminary data showed that the combination of sitravatinib (MGCD516) and tislelizumab (BGB-A317) is well tolerated and may promote antitumor activity when administered to patients with platinum-resistant ovarian cancer, according to a press release from BieGene, Ltd, which … Read more